Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.49 |
| ▸ | PDE4A | P27815 | 2/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.49 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30657430 | 1.00 | KDM1A (0.56) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL26636285 | 0.90 | KDM1A (0.47) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL30735441 | 0.90 | KDM1A (0.47) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL26636291 | 0.90 | KDM1A (0.47) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL69206 | 0.89 | KDM1A (0.56) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL19402410 | 0.88 | KDM1A (0.58) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL29079766 | 0.87 | KDM1A (0.55) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL29079727 | 0.87 | GPR119 (0.55) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL31575036 | 0.85 | KDM1A (0.49) | KDM1AGPR119PDE4BPDE4DPDE4A | |
| SCHEMBL30663106 | 0.85 | KDM1A (0.49) | KDM1AGPR119PDE4BPDE4DPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4519272-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023215449-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288683-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2L1, BCL2, BCL2L10 | KDM1A 375/4885GPR119 3957/4885PDE4B 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.